» Articles » PMID: 27566560

A Pyrazolo[3,4-d]pyrimidine Compound Inhibits Fyn Phosphorylation and Induces Apoptosis in Natural Killer Cell Leukemia

Abstract

Natural killer (NK) cell neoplasms are characterized by clonal proliferation of cytotoxic NK cells. Since there is no standard treatment to date, new therapeutic options are needed, especially for NK aggressive tumors. Fyn tyrosine kinase has a key role in different biological processes, such as cell growth and differentiation, being also involved in the pathogenesis of hematologic malignancies. Our previous studies led us to identify 4c pyrazolo[3,4-d]pyrimidine compound capable of inhibiting Fyn activation and inducing apoptosis in different cancer cell lines. Here we investigated the presence of Fyn and the effect of its inhibitor in NK malignant cells. Firstly, we showed Fyn over-expression in NK leukemic cells compared to peripheral blood mononuclear cells from healthy donors. Subsequently, we demonstrated that 4c treatment reduced cell viability, induced caspase 3-mediate apoptosis and cell cycle arrest in NK cells. Moreover, by inhibiting Fyn phosphorylation, 4c compound reduced Akt and P70 S6 kinase activation and changed the expression of genes involved in cell death and survival in NK cells. Our study demonstrated that Fyn is involved in the pathogenesis of NK leukemia and that it could represent a potential target for this neoplasm. Moreover, we proved that Fyn inhibitor pyrazolo[3,4-d]pyrimidine compound, could be a started point to develop new therapeutic agents.

Citing Articles

Advances in the expression and function of Fyn in different human tumors.

Liu C, Li S, Tang Y Clin Transl Oncol. 2023; 25(10):2852-2860.

PMID: 37093456 DOI: 10.1007/s12094-023-03167-9.


Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis Through the Release of Extracellular Vesicles.

Trino S, Laurenzana I, Lamorte D, Calice G, De Stradis A, Santodirocco M Front Oncol. 2022; 12:824562.

PMID: 35371979 PMC: 8965808. DOI: 10.3389/fonc.2022.824562.


Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells.

Abreu Miranda M, Marcato P, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni S Mater Sci Eng C Mater Biol Appl. 2020; 119:111460.

PMID: 33321591 PMC: 8694857. DOI: 10.1016/j.msec.2020.111460.


dvances in Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization.

Lamorte D, Faraone I, Laurenzana I, Trino S, Russo D, Rai D Molecules. 2020; 25(21).

PMID: 33105817 PMC: 7660062. DOI: 10.3390/molecules25214890.


Expression Analysis of Fyn and Bat3 Signal Transduction Molecules in Patients with Chronic Lymphocytic Leukemia.

Hosseini-Valiki F, Taghiloo S, Tavakolian G, Amjadi O, Tehrani M, Hedayatizadeh-Omran A Asian Pac J Cancer Prev. 2020; 21(9):2615-2621.

PMID: 32986360 PMC: 7779459. DOI: 10.31557/APJCP.2020.21.9.2615.


References
1.
Kawada J, Ito Y, Iwata S, Suzuki M, Kawano Y, Kanazawa T . mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res. 2014; 20(21):5412-22. DOI: 10.1158/1078-0432.CCR-13-3172. View

2.
Chougule R, Kazi J, Ronnstrand L . FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. Oncotarget. 2016; 7(9):9964-74. PMC: 4891096. DOI: 10.18632/oncotarget.7128. View

3.
Tintori C, Laurenzana I, La Rocca F, Falchi F, Carraro F, Ruiz A . Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. ChemMedChem. 2013; 8(8):1353-60. DOI: 10.1002/cmdc.201300204. View

4.
Elias D, Vever H, Laenkholm A, Gjerstorff M, Yde C, Lykkesfeldt A . Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2014; 34(15):1919-27. DOI: 10.1038/onc.2014.138. View

5.
Oakes V, Wang W, Harrington B, Lee W, Beamish H, Chia K . Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle. Cell Cycle. 2014; 13(20):3302-11. PMC: 4615124. DOI: 10.4161/15384101.2014.949111. View